Invivyd Stock Price, News & Analysis

Invivyd (NASDAQ: IVVD) announced U.S. FDA clearance of its IND and alignment on the REVOLUTION clinical program for VYD2311, a vaccine‑alternative monoclonal antibody to prevent COVID. The company plans two trials: DECLARATION (Phase 3, BLA‑enabling, ~2,000 participants; single IM dose and monthly dosing arms) and LIBERTY (active‑controlled safety/tolerability vs. mRNA vaccine, ~300 participants with co‑administration arm subject to final FDA alignment). Trials aim to start around year‑end 2025 with top‑line data anticipated mid‑2026. Invivyd says commercial launch quantities are available and trials are funded by a recent capital raise.

Invivyd (NASDAQ: IVVD) has appointed Dr. Paul B. Bolno to its Board of Directors and Compensation Committee. Dr. Bolno, who currently serves as President and CEO of Wave Life Sciences, brings extensive experience in pipeline development and technological platforms for creating new medical products.

The appointment comes as Invivyd focuses on developing solutions for viral infectious diseases, particularly in the areas of COVID-19 prevention and treatment. Dr. Bolno also serves on the Board of ExpressionEdits and chairs the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator.

Invivyd (Nasdaq: IVVD) has appointed Kristie Kuhl as Chief Communications Officer to lead the company's communications and patient advocacy initiatives. Kuhl, recognized in PRWeek's 2024 Health Influencer 30, joins from Zeno Group where she served as Global Managing Director of Health & Wellness.

In her new role, Kuhl will focus on advancing understanding of Invivyd's work in developing monoclonal antibodies for viral disease prevention and treatment, while building stakeholder trust and supporting company growth. Her appointment comes at a strategic time as Invivyd aims to strengthen its scientific credibility and relationships with key healthcare stakeholders.

Invivyd (Nasdaq: IVVD) announced its participation in two upcoming investor conferences in New York. The company will participate in fireside chats at the Cantor Global Healthcare Conference on September 3, 2025, at 2:10 PM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 12:00 PM ET.

The presentations will be available via live webcasts on the company's investor website and archived for approximately 30 days. Management will also host investor meetings during both conferences.

Invivyd (Nasdaq: IVVD) has successfully closed its public offering, raising $57.5 million in gross proceeds. The offering included 89.2 million shares of common stock at $0.52 per share and 21.3 million pre-funded warrants at $0.5199 each. The underwriter, Cantor, fully exercised its option to purchase an additional 14.4 million shares.

The financing was led by RA Capital Management and Janus Henderson Investors. Funds will support the VYD2311 clinical program, research in RSV and measles, and advancement of the SPEAR Study Group's efforts regarding Long COVID and COVID-19 Post-Vaccination Syndrome treatments.

Invivyd (Nasdaq: IVVD) has announced the pricing of a $50 million public offering, consisting of 74,811,404 shares of common stock at $0.52 per share and pre-funded warrants for 21,342,442 shares at $0.5199 per warrant.

The company has granted underwriters a 30-day option to purchase up to 14,423,076 additional shares. The offering, managed by Cantor as sole book-runner, is expected to close around August 22, 2025. Proceeds will fund the VYD2311 clinical program, research in RSV and measles, SPEAR Study Group efforts for Long COVID research, and general corporate purposes.

Invivyd (Nasdaq: IVVD) has announced a proposed underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares at the public offering price. Cantor will serve as the sole book-running manager.

The proceeds will fund multiple initiatives including the VYD2311 clinical program, research and development of pipeline programs for RSV and measles, and advancement of the SPEAR Study Group's research on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome. The offering will be made through a shelf registration statement previously filed with the SEC.

Invivyd (NASDAQ:IVVD) has announced that its COVID-19 antibody PEMGARDA® (pemivibart) and its next-generation candidate VYD2311 maintain strong neutralizing activity against the dominant XFG ("Stratus") SARS-CoV-2 variant. The company reports that COVID-19 cases are rising, with high viral activity in 12 states and growing infections in 34 states according to CDC data.

PEMGARDA, which is FDA-authorized for pre-exposure prophylaxis in certain immunocompromised patients, has demonstrated consistent effectiveness against all clinical variants since the Omicron BA.2 lineage. The company will submit new in vitro neutralization data to the FDA for inclusion in PEMGARDA's Healthcare Provider Fact Sheet.

Invivyd (NASDAQ: IVVD) reported Q2 2025 financial results, highlighting $11.8 million in PEMGARDA® net product revenue, representing 413% year-over-year growth. The company announced positive Phase 1/2 data for VYD2311, their COVID-19 monoclonal antibody candidate, demonstrating favorable safety and a 76-day half-life for intramuscular administration.

The FDA has aligned on a rapid pathway to full approval (BLA) for VYD2311. The company's pipeline expansion includes RSV and measles candidates, with updates expected in Q3 and Q4 2025. Financial results showed a net loss of $14.7 million ($0.12 per share), improved from $47.2 million loss in Q2 2024, with $34.9 million in cash as of June 30, 2025.